Shingrix is a vaccine that helps prevent shingles, a painful rash caused by the chickenpox virus waking up again. It is given as two shots into the arm muscle, a few months apart. It works by boosting the immune system so it can keep the virus in check.
Every report comes from a Lived member, sent anonymously.
Have you tried Shingrix (Zoster Vaccine Recombinant) for Shingles?
Shingrix (zoster vaccine recombinant, adjuvanted) is a vaccine that prevents shingles, a painful rash that typically appears on one side of the body. Shingles happens when the chickenpox virus, which stays dormant in the body after a chickenpox infection, becomes active again. In the US, Shingrix is approved for adults aged 50 and older, and for adults 18 and older whose immune system is or will be weakened by a disease or its treatment, such as a blood cancer, a transplant, HIV or medicines that suppress the immune system. The vaccine advisory committee of the Centers for Disease Control and Prevention (CDC) recommends it for healthy adults 50 and older and for immune-compromised adults from age 19. Preventing shingles also prevents its most troublesome complication, postherpetic neuralgia: nerve pain that lingers for months or longer after the rash has healed. Shingrix is recommended for people who have already had shingles, because shingles can come back, and for people who received Zostavax, an older live shingles vaccine no longer available in the US since 2020. It does not treat an active shingles outbreak or existing nerve pain, and it is not used to prevent chickenpox.
After chickenpox, the varicella zoster virus hides in nerve cells for life. The immune system normally keeps it inactive, but that control fades with age and with illnesses or treatments that suppress immunity. This is why shingles becomes more common later in life and in people with weakened immune systems. Shingrix contains no live virus. It holds one purified protein from the surface of the virus, called glycoprotein E, combined with an adjuvant, an added ingredient that makes the immune response stronger than the protein alone would. Vaccination boosts the immune system's specific response to the virus, which is thought to be how it prevents the virus from reactivating. Because it cannot cause an infection, it can be given to people whose immune systems are weakened.
Shingrix is given as two injections into the muscle of the upper arm, by a pharmacist, nurse or doctor. For most adults, the second dose comes 2 to 6 months after the first. People who are or will soon be immune-compromised can have the second dose 1 to 2 months after the first, so protection is in place sooner. Both doses are needed. If more than 6 months pass before the second dose, the series does not start over; the second dose is simply given late. A second dose given less than 4 weeks after the first does not count and has to be repeated. Shingrix can be given at the same visit as other adult vaccines, such as flu, pneumococcal, tetanus and COVID-19 vaccines, at a different injection site. For someone expecting treatment that weakens the immune system, such as chemotherapy or a transplant, vaccinating beforehand gives the best chance of a strong response. Otherwise, it is usually timed for a period when the illness is stable and immune suppression is lighter.
Reactions in the few days after a dose are common and can be strong enough to disrupt plans. In the main trials of adults 50 and older, about three in four people had a sore arm, and roughly a third had redness or swelling where the shot was given. Muscle aches and tiredness each affected nearly half, headache over a third, and shivering, fever or stomach upset were less common. About 1 in 10 people aged 50 to 59 had arm pain bad enough to stop normal activities. These reactions usually last 2 to 3 days, are less frequent in people 70 and older, and can happen after either dose. In some people the arm stays stiff or hard to move for a week or more. Shingrix carries a small increased risk of Guillain-Barré syndrome (GBS), a rare condition in which the immune system attacks the nerves, during the 6 weeks after vaccination. In studies of Medicare patients 65 and older, this amounted to roughly 3 to 7 extra cases per million doses, seen after the first dose but not the second. GBS usually begins with weakness or tingling in the legs that can spread upward; weakness, tingling, trouble speaking or swallowing, or vision changes after vaccination need medical attention right away. Hives, swelling of the face or throat, or difficulty breathing after a dose can signal a severe allergic reaction: call 911. Fainting can happen right after any injection, so tell the person giving the vaccine if you feel dizzy or lightheaded.
Shingrix should not be given to anyone who had a severe allergic reaction, such as anaphylaxis, to a previous dose or to any of its ingredients. Tell the person giving the vaccine about past reactions to vaccines and about any current illness; a moderate or severe illness, with or without fever, is usually a reason to wait. Someone who has shingles right now should wait until the acute illness is over and symptoms have settled. There is not enough information to know whether Shingrix poses a risk in pregnancy, so vaccination is usually postponed until after pregnancy. A pregnancy test is not needed beforehand. Breastfeeding is not a reason to delay. The Shingrix label lists no drug interactions. Because it contains no live virus, it can be given while someone is taking antiviral medicines, such as those used for herpes or shingles. Treatments that suppress the immune system can weaken the response to the vaccine, which is why timing around them matters. Taking pain relievers or fever reducers in advance to prevent reactions is generally not recommended, but they can be used afterward to treat symptoms.
Protection is strong in adults with healthy immune systems. In one large trial, two doses cut the risk of shingles by about 97% in adults 50 and older; in a second trial of adults 70 and older, the reduction was about 90%, and postherpetic neuralgia was reduced by about 85%. These trials followed people for roughly three to four years. A later follow-up of the same volunteers, to a median of about 11 years after vaccination, found shingles rates had risen somewhat but remained well below the rates seen in the original unvaccinated comparison groups. That follow-up had no placebo group of its own, so it is less certain than the original trials. In people with weakened immune systems, protection is lower but still meaningful: about 68% in adults who had an autologous stem cell transplant (a transplant using their own stem cells), and about 87% in a smaller, less precise analysis of people with blood cancers. Shingles can still occur after vaccination, though much less often. Plan around the possibility of a rough day or two after each dose. Even if the first dose caused strong reactions, completing the series is recommended unless the reaction was a severe allergic one, because both doses are needed for full protection.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Shingrix (Zoster Vaccine Recombinant), what you've noticed, or ask the community a question.